Confirming the Diagnosis: Imaging and Genetics
At a Glance
Canavan disease is definitively diagnosed through a combination of physical symptoms like a large head size, an MRI/MRS showing high N-acetylaspartic acid (NAA) levels in the brain, and genetic testing confirming mutations in both copies of the ASPA gene.
Getting an accurate diagnosis for Canavan disease involves a series of steps that move from identifying outward physical symptoms to pinpointing the exact chemical and genetic cause. While several rare diseases share similar features, the diagnostic markers for Canavan disease are exceptionally distinct.
The Triad of Diagnosis
Doctors typically look for three key pieces of evidence to confirm a diagnosis of Canavan disease:
- Clinical Symptoms: The combination of low muscle tone (hypotonia) and a large head size (macrocephaly) in an infant [1][2].
- Imaging (MRI and MRS): Pictures of the brain that show specific patterns of white matter damage [1].
- Biochemical and Genetic Testing: Measuring a specific chemical in the body and looking at the child’s DNA [3][1].
Brain Imaging: MRI and MRS
When a neurologist suspects a leukodystrophy (a disease that affects the brain’s white matter), they will order an MRI.
- MRI (Magnetic Resonance Imaging): In Canavan disease, the MRI usually shows diffuse, symmetric “whiteness” in the white matter, indicating it is damaged or missing [1]. A specific sign is the involvement of subcortical U-fibers, which are small connections just beneath the brain’s surface [1][4].
- MRS (MR Spectroscopy): This is a specialized test done during the MRI that measures chemicals in the brain. In Canavan disease, the MRS will show a massive “peak” or elevation of a chemical called N-acetylaspartic acid (NAA) [1][4]. This finding is often considered the most definitive clue because Canavan is one of the only conditions where NAA levels are this high [1][5].
Biochemical and Genetic Testing
To confirm what the MRS shows, doctors will test for NAA levels and the gene that causes the buildup.
- NAA Levels: High levels of NAA will also be present in the child’s urine and blood [1][4]. Finding elevated NAA in the urine is a classic way to confirm the diagnosis [6].
- Genetic Testing: The “gold standard” for diagnosis is identifying mutations in both copies of the ASPA gene [3][7]. This test confirms that the body cannot produce the enzyme needed to break down NAA [3].
Why Genetic Confirmation Matters: “Look-Alike” Conditions
Because Canavan disease causes macrocephaly (a large head) and white matter damage, it can sometimes be confused with other rare disorders. Getting the genetic test to confirm the MRI is vital because long-term care, prognosis, and potential clinical trial eligibility are vastly different for each condition [6][1].
| Condition | Shared Feature | Key Difference from Canavan |
|---|---|---|
| Alexander Disease | Large head size; white matter damage | Usually affects the front of the brain first; does not have high NAA levels [8]. |
| Megalencephalic Leukodystrophy (MLC) | Large head size; white matter damage | Characterized by specific subcortical cysts on the MRI; does not have high NAA levels [8]. |
Confirmation via ASPA genetic testing ensures your child is on the correct path for specialized care and avoids the uncertainty of living with an unconfirmed “presumed” diagnosis [7][9].
Common questions in this guide
How is Canavan disease diagnosed?
What does an MRI show for a child with Canavan disease?
What is the significance of high NAA levels?
Why is ASPA genetic testing necessary?
How do doctors distinguish Canavan disease from Alexander disease?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Can you show me the NAA peak on my child's MR spectroscopy (MRS) report and explain what the levels were?
- 2.Does the MRI show involvement of the subcortical U-fibers or any specific sparing of brain structures?
- 3.What specific mutations were found in my child's ASPA gene, and are they considered 'severe' or 'mild' variants?
- 4.How do we definitively rule out Alexander disease or Megalencephalic Leukodystrophy (MLC) based on these results?
- 5.Is the diagnosis based on biochemical findings (urine/blood) or is it fully confirmed by genetic testing?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (9)
- 1
Canavan Disease: Clinical and Laboratory Profile from Southern Part of India.
Gowda VK, Bharathi NK, Bettaiah J, et al.
Annals of Indian Academy of Neurology 2021; (24(3)):347-350 doi:10.4103/aian.AIAN_386_20.
PMID: 34446995 - 2
Canavan's spongiform leukodystrophy (Aspartoacylase deficiency) with emphasis on sonographic features in infancy: description of a case report and review of the literature.
Rossler L, Lemburg S, Weitkämper A, et al.
Journal of ultrasound 2023; (26(4)):757-764 doi:10.1007/s40477-022-00667-2.
PMID: 35187608 - 3
Development of bisubstrate analog inhibitors of aspartate N-acetyltransferase, a critical brain enzyme.
Mutthamsetty V, Dahal GP, Wang Q, Viola RE
Chemical biology & drug design 2020; (95(1)):48-57 doi:10.1111/cbdd.13586.
PMID: 31260162 - 4
Cribriform Appearance of White Matter in Canavan Disease Associated with Novel Mutations of ASPA Gene.
Bhat MD, Manjunath N, Kumari R, et al.
Journal of pediatric genetics 2022; (11(4)):267-271 doi:10.1055/s-0041-1725118.
PMID: 36267868 - 5
Leukodystrophy with multiple beaded periventricular cysts: unusual cranial MRI results in Canavan disease.
Drenckhahn A, Schuelke M, Knierim E
Journal of inherited metabolic disease 2015; (38(5)):983-4 doi:10.1007/s10545-015-9812-1.
PMID: 25647544 - 6
Atypical clinical and radiological course of a patient with Canavan disease.
Sarret C, Boespflug-Tanguy O, Rodriguez D
Metabolic brain disease 2016; (31(2)):475-9 doi:10.1007/s11011-015-9767-9.
PMID: 26586007 - 7
Deep Intronic SVA_E Retrotransposition as a Novel Factor in Canavan Disease Pathogenesis.
Weiß M, Selig M, Friedrich J, et al.
Human gene therapy 2025; (36(17-18)):1248-1256 doi:10.1089/hum.2025.006.
PMID: 40257001 - 8
Epilepsy in children with leukodystrophies.
Zhang J, Ban T, Zhou L, et al.
Journal of neurology 2020; (267(9)):2612-2618 doi:10.1007/s00415-020-09889-y.
PMID: 32388833 - 9
Human induced pluripotent stem cell line (SDQLCHi064-A) derived from a patient with Canavan disease carrying c.556_559dup GTTC and c.919delA mutations in the ASPA gene.
Liu N, Ge Y, Yang Y, et al.
Stem cell research 2024; (76()):103325 doi:10.1016/j.scr.2024.103325.
PMID: 38309148
This page explains the diagnostic process for Canavan disease for educational purposes only. Always consult your pediatric neurologist or geneticist to interpret your child's specific MRI, MRS, and genetic test results.
Get notified when new evidence is published on Canavan disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.